Phenylketonuria patients harboring a subset of phenylalanine hydroxylase (PAH) mutations have recently shown normalization of blood phenylalanine levels upon oral administration of the PAH cofactor tetrahydrobiopterin [(6R)-L-erythro-5,6,7,8-tetrahydrobiopterin (BH4)]. Several hypotheses have been put forward to explain BH 4 responsiveness, but the molecular basis for the corrective effect(s) of BH4 has not been understood. We have investigated the biochemical, kinetic, and structural changes associated with BH4-responsive mutations (F39L, I65T, R68S, H170D, E178G, V190A, R261Q, A300S, L308F, A313T, A373T, V388M, E390G, P407S, and Y414C). The biochemical and kinetic characterization of the 15 mutants studied points toward a multifactorial basis for the BH4 responsiveness; the mutants show residual activity (>30% of WT) and display various kinetic defects, including increased Km (BH4) and reduced cooperativity of substrate binding, but no decoupling of cofactor (BH4) oxidation. For some, BH4 seems to function through stabilization and protection of the enzyme from inactivation and proteolytic degradation. In the crystal structures of a phenylketonuria mutant, A313T, minor changes were seen when compared with the WT PAH structures, consistent with the mild effects the mutant has upon activity of the enzyme both in vitro and in vivo. Truncations made in the A313T mutant PAH form revealed that the N and C termini of the enzyme influence active site binding. Of fundamental importance is the observation that BH4 appears to increase Phe catabolism if at least one of the two heterozygous mutations has any residual activity remaining.
Phenylketonuria patients harboring a subset of phenylalanine hydroxylase (PAH) mutations have recently shown normalization of blood phenylalanine levels upon oral administration of the PAH cofactor tetrahydrobiopterin [(6R)-L-erythro-5,6,7,8-tetrahydrobiopterin (BH4)]. Several hypotheses have been put forward to explain BH
responsiveness, but the molecular basis for the corrective effect(s) of BH4 has not been understood. We have investigated the biochemical, kinetic, and structural changes associated with BH4-responsive mutations (F39L, I65T, R68S, H170D, E178G, V190A, R261Q, A300S, L308F, A313T, A373T, V388M, E390G, P407S, and Y414C). The biochemical and kinetic characterization of the 15 mutants studied points toward a multifactorial basis for the BH4 responsiveness; the mutants show residual activity (>30% of WT) and display various kinetic defects, including increased Km (BH4) and reduced cooperativity of substrate binding, but no decoupling of cofactor (BH4) oxidation. For some, BH4 seems to function through stabilization and protection of the enzyme from inactivation and proteolytic degradation. In the crystal structures of a phenylketonuria mutant, A313T, minor changes were seen when compared with the WT PAH structures, consistent with the mild effects the mutant has upon activity of the enzyme both in vitro and in vivo. Truncations made in the A313T mutant PAH form revealed that the N and C termini of the enzyme influence active site binding. Of fundamental importance is the observation that BH4 appears to increase Phe catabolism if at least one of the two heterozygous mutations has any residual activity remaining. M ost forms of phenylketonuria (PKU) and hyperphenylalaninemia (HPA) are caused by mutations in the phenylalanine hydroxylase (PAH; EC 1.14.16.1) gene, resulting in a nonfunctional enzyme that in turn leads to an accumulation of the L-Phe substrate in blood and brain (1) . PAH is a nonheme iron-dependent enzyme that requires (6R)-L-erythro-5,6,7,8-tetrahydrobiopterin (BH 4 ) as an essential cofactor in the hydroxylation of L-Phe and also uses dioxygen as a substrate. The gene for PAH has been cloned and Ͼ400 disease-causing mutations identified (www.pahdb.mcgill.ca) (2) . An L-Phe-restricted diet can ameliorate the effects of high blood L-Phe levels on cognitive function. However, treatment has to be continued ''for life''; otherwise, the effect of high L-Phe levels leads to functional deficits (3) .
Recently, certain PKU patients have been responsive to BH 4 loading, resulting in a decreased L-Phe level. It was suggested that this response was due to a K m mutant PAH enzyme (4). Kure et al. (5) investigated four patients with HPA who responded to the BH 4 loading test using 10 mg of BH 4 ͞kg body weight. In all four patients, BH 4 defects were excluded, and mutations detected in the PAH gene. After this report, many additional cases have appeared (6) (7) (8) (9) (10) (11) . These reports emphasize the potential response to BH 4 of patients with mild PKU. A database that contains a current listing of the BH 4 -responsive genotypes has been established at www.bh4.org͞biopku.html.
Due to the large potential of response among PKU patients [i.e., up to Ϸ60% of HPA patients (12) ], pilot studies have been undertaken to determine how many patients would respond to BH 4 . These studies include patients with classical as well as atypical PKU in addition to HPA, and many classical PKU patients were found to be BH 4 -responsive in addition to the HPA patients (13) . In the wake of the clinical studies, we set out on a biochemical and biophysical investigation to study the in vitro mechanisms of BH 4 responsiveness in HPA and PKU patients. Several possibilities have previously been put forward to explain the BH 4 response in mild PKU (14) : (i) decreased affinity of the mutant PAH for BH 4 ; (ii) stabilization of the active tetramer͞dimer forms of the mutant proteins and protection from proteolytic cleavage, i.e., BH 4 can act as a chemical chaperone preventing misfolding (15) and subsequent ubiquitin-dependent proteosomal degradation; (iii) up-regulation of PAH gene expression (16); (iv) BH 4 -induced change in BH 4 biosynthesis; and (v) PAH mRNA stabilization, as shown for nitric oxide synthase (17) . The expression, kinetic, and binding characterization analyses presented here, applied on the mutations in the clinical study plus others (Table 1) , contribute to the understanding of BH 4 responsiveness in PKU and to a more accurate selection of genotypes that are predictably associated with a positive response to cofactor treatment. HPLC and fluorescence detection of L-Tyr for nonactivated (non-L-Phe preincubated) and activated (L-Phe preincubated, 1 mM L-Phe) PAH enzymes were performed as described (18) . Isothermal titration calorimetry (ITC) experiments were performed in a VP-ITC titration calorimeter (Microcal, Amherst, MA) at pH 7.0 with the glucose oxidase system (19) and 10-50 M PAH subunit with Ϸ0.5 mol ferrous ammonium sulfate͞subunit, as described (20) . Additional information on the biophysical characterization is available in Table 3 , which is which is published as supporting information on the PNAS web site.
Crystallization and Data Collection. Purified protein at a concentration of Ϸ10 mg͞ml of the four mutants (H170D, R261Q, A313T, and Y414C) of double-truncated PAH (dt-PAH) were used for crystallization trials. Only the A313T-dt-PAH mutant crystallized using 5-10% ethylene glycol͞20-40 mM Pipes, pH 6.8͞8-15% polyethylene glycol 2000. Two data sets were collected on the A313T-dt-PAH and Ϸ6 mM 7,8-BH 2 cocrystallized A313T-dt-PAH crystals (denoted A313T-dt-PAH⅐7,8-BH s ) on an in-house FRD generator (Rigaku͞MSC, Tokyo) (wavelength ϭ 1.5418 Å) with an R-axis IVϩϩ image plate detactor, by using Osmic mirrors and an X-stream cryostat set to 100 K. Data were processed with HKL2000 (21) to 2.1 and 2.2 Å for the apo-A313T-dt-PAH and A313T-dt-PAH⅐7,8-BH 2 , respectively. The structures were phased by using molecular replacement [PDB ID code 1PAH (22) and PDB ID code 1LRM (23)] for the two structures, respectively. Electron density for a threonine residue at position 313 was clear in the initial maps in both structures, and the entire 7,8-BH 2 ligand was readily visible in electron density. Map calculations, energy minimization, and refinement were performed by using the program CNS (Ver. 1.1) (24) . The program O (Ver. 7) (25) was used to manually fit the differences from the native structures into the experimental electron density. Final agreement statistics are R cryst 0.21 for both structures and R free 0.24 and 0.25 for the apo and BH 4 bound structures, respectively. The remaining final model statistics are listed in Table 4 , which is published as supporting information on the PNAS web site. Additional information related to the protocols for mutagenesis, expression, purification, and biophysical analysis (isothermal titration calorimetry, circular dichroism, and structure determination) may be found in Supporting Text, which is published as supporting information on the PNAS web site.
Results
Kinetic Characterization of PKU Mutant Proteins. Fifteen mutations plus WT of full-length human PAH were expressed in E. coli as fusion proteins with maltose-binding protein and purified to homogeneity. The location of mutations characterized in this study is mapped onto the composite model of a monomer of PAH (26) in Fig. 1 . The mutations can be found throughout the structure, and not just in the catalytic domain regions involved in the binding of the BH 4 cofactor. They are in the regulatory domain (F39L, I65T, and R68S), the catalytic domain (H170D, E178G, V190A, R261Q, A300S, L308F, A313T, A373T, V388M, E390G, and P407S), and the dimerization motif in the oligomerization domain (Y414C). The putative structural effects of the BH 4 -responsive mutations included in this study and the percent reduction of L-Phe in patient genotypes from the clinical study can be found in Table 1 . The relative in vitro activities of purified mutant enzymes are summarized in Table 4 . Eight of the mutations studied here have either not been reported previously or to our knowledge, neither been reported expressed in vitro nor activity measured. All mutants studied have Ͼ30% residual activity as compared with wt-PAH (except for V388M, which has 23% residual activity).
Detailed analyses of the steady-state kinetic parameters were performed for all full-length PAH mutations ( Table 2 ). All of the mutants presented various kinetic defects when compared with wt-PAH, and only H170D, V190A, A373T, and P407S showed similar response to L-Phe binding, both as activation fold by preincubation with the substrate and degree of positive binding cooperativity (h, Hill coefficient). Significantly decreased apparent affinity for BH 4 was observed for the mutants F39L, I65T, and L308F. Some mutants were obtained in the amounts required to perform isothermal titration calorimetry measurements and the thermodynamic binding parameters for BH 4 could be determined (Table 5 , which is published as supporting information on the PNAS web site, and ref. 20) . Defective BH 4 binding was confirmed by this technique for F39L and R68S, whereas I65T and A313T also showed a slightly decreased affinity. In all cases, the decreased affinity appears to be caused by an increased entropic penalization to the enthalpically driven BH 4 -binding process.
Coupling of BH4 Oxidation to L-Tyr Formation. The hydroxylation reaction in wt-PAH is tightly coupled to the oxidation of the natural cofactor BH 4 . Recently, two severe PKU mutations, R158Q and E280K, were found to display a decoupled oxidation of the cofactor (22) . These mutants, which are at locations important for maintaining the correct shape of the active site, both oxidize pterin at more than twice the rate of WT enzyme, and the reactions are only Ϸ20% coupled to production of L-Tyr. Incorrect formation of the cofactor-binding site would thus seem to be deleterious for coupling efficiency. We therefore analyzed the coupling efficiency of a number of selected BH 4 responsive mutations from our study, including some with defective BH 4 binding. The changes in stability, activity, binding affinity, and cooperativity seen in the mutants studied here are not reflected in a decoupling of cofactor (BH 4 ) oxidation upon hydroxylation of substrate (Table 2) , as would be expected if the binding site for BH 4 had been structurally altered to a large extent due to a mutation, with consequent defective formation of a five-coordinate Fe(II)-L-Phe-BH 4 complex (27) . The decoupling observed in a previous study on the R158Q and E280K mutations was found to be a result of a distortion of the Fe(II) ligation and BH 4 binding. Theoretical calculations (28) support the findings on BH 4 decoupling in the more severe mutants, because the initial formation of a pterin-peroxy intermediate can occur only if BH 4 is properly oriented for formation of an Fe-OO- 
BH 4 bridge and an open coordination position is available on the Fe(II).
The Effect of BH4 on the Stability of PAH Mutants. The effect of BH 4 on the stability of the proteins was first studied by measuring the thermostability by circular dichroism spectroscopy of wt-PAH and mutants R68S and A300S in the presence and absence of BH 4 , essentially as described (29) . The thermal denaturation of fulllength PAH results in two unfolding transitions with melting temperature (T m ) values at 45-46 and 54°C, corresponding to the N-terminal regulatory and C-terminal catalytic domains of wt-PAH, respectively. The addition of BH 4 results in a concentrationdependent increase of T m for both transitions, with end points at 49°C and 59°C for the regulatory and catalytic domains, respectively, at 250 M BH 4 . R68S was found to be similarly stabilized by BH 4 , with the only difference from wt-PAH being the concentration of BH 4 for maximal thermal stabilization (500 M), a finding that could be related to its reduced affinity (K d ) for BH 4 (Table 2) . Thus, for the mutant A300S, with an affinity for BH 4 similar to wt-PAH (Table 2) , the circular dichroism-measured T m values and the concentration of BH 4 for maximal stabilization were found to be similar to wt-PAH. To further analyze the putative chemical chaperone effect of BH 4 , correcting misfolding and proteolytic degradation of the mutant proteins, we have used pulse-chase analysis after in vitro synthesis in the cell-free in vitro transcriptiontranslation (TnT) system (30, 31) . We measured the half-life of the proteins after synthesis in the TnT system and found that all mutants tested except R68S and A300S degraded more rapidly than wt-PAH (Table 4) , indicative of folding defects of varying degrees. Interestingly, a significant increase in half-life was observed for V388M and Y414C, whereas for F39L, A373T, and E390G, a slight stabilization in half-life was observed.
Structural Determination of the A313T-PAH BH4-Responsive Mutant.
To investigate the effects of the BH 4 -responsive mutations on the structure of PAH, we tried to crystallize several mutant forms from this study. Double-truncated (N-and C-terminal) and singletruncated (C-terminal) PAH does crystallize, and many structures of these forms of human and rat PAH have been determined in our lab (22, (32) (33) (34) (35) . In this study, only one mutant crystallized: the A313T dt-PAH mutant. X-ray diffraction data were collected for both ligand-free and 7,8-BH 2 -bound A313T dt-PAH (Table 6 , which is published as supporting information on the PNAS web site). The structure of mutant A313T-dt-PAH is shown in Fig. 2B . A superposition of the WT dt-hPAH structures with and without 7,8-BH 2 , and A313T-dt-PAH structures determined in the current study, with and without 7,8-BH 2 , and a plot showing the residual differences (rms deviation, RMSD) among the same structures are shown in Figs. 3 and 4 , which are published as supporting information on the PNAS web site. Small individual differences were observed between the mutant and WT, ligand-bound, and nonligand-bound dt-PAH structures. The overall RMSD of the WT dt-hPAH structure (PDB ID code 1PAH) versus the WT dt-PAH structure with 7,8-BH 2 bound (32) is 0.26 Å. The pterin-binding region between amino acids 245 and 250 was found to move Ϸ1.3 Å in the direction of the iron, thus allowing several important hydrogen bonds to the pterin ring to be formed upon cofactor binding in the WT dt-PAH enzyme (32) . This induced fit-type of cofactor binding is believed to be necessary to form an active site that is properly arranged for L-Phe and O 2 binding (32) (33) (34) . In the A313T dt-PAH mutant structure, only four regions appear to have shifted as compared with the WT dt-PAH structure (1PAH) (Figs. 3 and 4) . These are located in the pterinbinding region (amino acids 247 and 248) and regions 336-339, the 380s loop (residues 377-379), and residues 411-414. No large differences are seen when comparing the A313T-PAH and A313T- 
Discussion
Most BH 4 -responsive patients have a mild HPA or moderate PKU phenotype and harbor at least one associated missense mutation, although some classic PKU patients have been found to be BH 4 responsive (13) . This observation suggests that some residual PAH activity (in vivo) is a prerequisite for BH 4 responsiveness, and that mutations causing severe structural distortion in the expressed protein leading to undetectable PAH activity are not likely to be stimulated by BH 4 . In our kinetic characterization of 15 BH 4 -responsive PAH mutants, we have found that all mutants studied have Ͼ30% residual activity as compared with wt-PAH (except V388M, which has 23% residual activity). In most of the mutations studied, some kinetic defects can be detected. A reduced apparent binding affinity for BH 4 , originally hypothesized as the reason for BH 4 -responsive PKU (5), however, was found in only a few mutants: F39L, I65T, and L308F. A clearly increased K d was observed by isothermal titration calorimetry only for the mutants F39L and R68S, both at the N-terminal domain of the enzyme. More relevant for interpreting BH 4 responsiveness are the results on the in vitro transcription-translation expression system, which suggests that the cofactor has a significant role as a chemical chaperone, preventing misfolding, degradation, or inactivation of mutant PAH. For the mutants F39L, A373T, V388M, E390G, and Y414C, an increase in the half-life (T 1/2 ) of mutant PAH was observed upon expression with BH 4 in the expression media. However, only for Y414C was the half-life restored to WT levels by BH 4 . The metabolic availability of BH 4 in vivo has been shown in hepatocytes to be sequestered by forming a PAH⅐BH 4 complex, which has much less activity and is less readily L-Phe-activated than the uncomplexed enzyme (35) . The less-active complex between BH 4 and PAH may play an important physiological role in that it can stabilize some mutants and wt-PAH and thus prevent the ubiquitin-dependent degradation (36) in resting situations in the absence of high concentrations of L-Phe. A nonspecific role for the cofactor in protecting not only PAH protein integrity, but also the activity of essentially all mutants, by preventing a chemical inactivation has recently been put forward (20) . Thus, the binding of BH 4 at saturating concentrations might additionally prevent peroxide formation due to uncoupled reactions [hydrogen peroxide is known to inactivate PAH (37, 38) ] and protect the right configuration of the active site in PKU mutants, independent of the location of the mutation.
Previous crystal structure determinations of truncated forms of PAH (22, (39) (40) (41) have shown that the monomer has a three-domain structure. The substrate L-Phe, which activates the tetrameric enzyme by cooperative homotropic binding, is proposed to induce a conformational change that displaces an N-terminal autoregulatory sequence from its position in the active site (40, 42) . The cofactor and cosubstrate BH 4 , on the contrary, acts as a negative regulator, blocking the L-Phe-binding site (43) . Recent structural and mutational studies of hinge-bending regions (41, 42, 44) have revealed further evidence that global activating conformational changes caused by L-Phe binding have the epicenter at the active site and are transmitted throughout the enzyme through hinge-bending motions. A reduction or loss of the cooperative substratedependent activation has been seen for most of the kinetically characterized PKU mutations to date (20, 45, 46) , severe as well as mild forms, suggesting that the enzyme is quite susceptible to mutations that destroy the cooperative activation mechanism probably by hindering the transmission of the conformational change. The kinetic Hill coefficient (h) shows that some of the mutants tested in our study displayed a complete loss of cooperativity, in particular the I65T, E178G, R261Q, A300S, and V388M mutants (h ϭ 1.1 or 1.0) ( Table 2 ). The other mutants have a slightly lowered h of between 1.4 and 2.0, as compared with 2.0 in wt-PAH. Three mutations stand out with increased h: H170D, V190A, and P407S (2.8, 2.9, and 2.1, respectively). The reason for this high cooperativity may be in the relatively high BH 4 -binding affinity [lower than WT K m (BH 4 )] observed for these three mutants (12 Ϯ 2, 17 Ϯ 2, and 17 Ϯ 3), as compared with wt-PAH [K m (BH 4 ) ϭ 26 Ϯ 3], whereas the substrate affinity is practically the same as for WT. These mutants also retain close to or higher than WT activation, with 2.5-, 4.2-, and 2.0-fold L-Phe activation. Thus, there must exist other, still unexplored, mechanisms for BH 4 responsiveness, in addition to a correction of catalytic defects (notably for the mutants with lower affinity for BH 4 ) and stabilization, in particular because these mutations with high affinity for BH 4 , which putatively would inhibit the enzyme reaction, are responsive in vivo.
Very recently, Kure et al. (47) presented in vivo results on BH 4 supplementation in PKU mice, showing an Ϸ35% increase in activity for normal (WT) animals upon treatment. Their concluding hypothesis was that the responsiveness to BH 4 in patients with PAH deficiency was due to the suboptimal physiological concentrations of BH 4 normally present in hepatocytes and to the enhancement of the residual activity upon supplementation to higher than physiological concentrations. A hepatic concentration of BH 4 of 5-10 M has been measured (48) (49) (50) . Michaelis-Menten kinetics tells us that the enzyme is not saturated at this concentration (K m ϭ 12-44 M; Table 2 ), and thus the activity will increase with increasing concentration of BH 4 . However, the concentration of BH 4 that is functional in both treated and nontreated animals during catalysis was not determined by Kure et al. (47) , and this issue remains to be investigated. Moreover, the observed modest increase in activity does not appear to be enough to explain the positive response and the rescue in most human BH 4 -responsive mutants and, more importantly, our results show specific effects of BH 4 on the mutant PAH protein and specific activity (ref. 20 and this work). Thus, after in vitro transcription translation synthesis in the presence of BH 4 , the activity measured at a fixed concentration of BH 4 (75 M, which is the standard used by most research groups) increases both in mutant and wt-PAH (20) .
Conclusion
The molecular mechanisms for BH 4 responsiveness potentially increase the amount of active enzyme in vivo, as well as mutant PAH activity. The BH 4 -responsive patients would therefore reach the lower-limit value of L-Phe hydroxylation, allowing the catabolism of L-Phe amounts usually present in normal diets. Based on the relatively high residual activity and generally small kinetic and structural defects of the responsive mutations studied here, it appears that this lower-limit or threshold value would be close to that of the heterozygous state, with a WT gene copy in combination with a functionally hemizygous null mutation. Importantly, we have been able to discern that the BH 4 response is mainly a result of a correction by BH 4 of PAH mutant kinetic defects and͞or stabilization defects, distributed throughout the PAH structure. However, all patients with mutations associated with any residual activity should be tested for BH 4 responsiveness to improve the current models.
